Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

September 13, 2023

Imcyse Announces Completion of Enrollment in Phase 1 Clinical Trial of ImotopeTM IMCY-0141 for the Treatment of Multiple Sclerosis

June 22, 2023

Imcyse joins CLAIMS, a European Health Initiative Project to Make Data-Driven Precision Medicine a Reality for Patients with Multiple Sclerosis

March 01, 2023

Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes

April 13, 2022

Imcyse Announces First Patient Dosed in Adaptive Phase 1/2 Clinical Trial of Imotope™ IMCY-0141 for Multiple Sclerosis

March 14, 2022

Imcyse to Present at Oppenheimer 32nd Annual Healthcare Conference

January 13, 2022

Imcyse Reports Positive Immune Response from Interim Analysis of Phase 2 IMPACT Type 1 Diabetes Study

November 03, 2021

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

June 24, 2021

Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth

June 24, 2021

INNODIA is ready for a new phase – clinical trials

February 17, 2021

Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder